Glenview Cuts CVS Holding To About 27% Of Its Prior Share Count
Humana holdings increased 2.1-fold as Glenview's disclosed portfolio grew to 140 positions from 45.
Glenview Capital Management cut its CVS holding to about 27% of its previous share count in the third quarter of 2026. The investment manager's quarterly SEC holdings filing, filed Monday, showed a contrasting 2.1-fold increase in Humana shares.
CVS Shrinks, Humana Grows
Glenview held 1.3 million CVS shares at quarter-end, down from 4.8 million in the prior quarter. The position's disclosed value fell to $109.6 million from $499.1 million, leaving CVS at about 2% of the disclosed book.
Humana's position reached 545,385 shares, valued at $208.1 million. Viatris moved in the opposite direction: Glenview reduced that holding to 209,983 shares from 9.9 million, with the remaining position worth $3.7 million.
The healthcare changes followed a quarter-end portfolio that included a $418.2 million Tenet Healthcare holding at June 30.
More Positions, A Larger Book
Glenview's total disclosed value reached $6.1 billion, including options notional, compared with $5.5 billion in the previous quarter. The number of disclosed positions increased to 140 from 45.
Meta's share count rose 1.4-fold to 495,268 from 356,841. Its quarter-end value was $359.2 million, accounting for about 6% of disclosed holdings.
Global Payments remained the largest disclosed holding at September 30, valued at $580.3 million. Glenview's position had been valued at $646.3 million at June 30.
The totals cover the holdings reported in a 13F, the quarterly SEC report large investors file for their U.S. stock holdings. Disclosed options are included; cash, bonds and short positions fall outside its scope.
Sources
- GLENVIEW CAPITAL MANAGEMENT LLC 13F-HR (Q3 2026) — SEC EDGAR